The United Kingdom government is weighing whether to implement a mass testing strategy that would involve using speed COVID-19 tests so the country's whole population could get tested each week from 2021.
According to The BMJ's recently published report, documents leaked from the...
Vir Biotechnology Inc. and GlaxoSmithKline plc revealed on Monday that the phase 2/3 study of their jointly developed coronavirus antibody treatment began last week.
VIR-7831 (or GSK4182136), which has been described by the companies as a "fully human" anti-coronavirus "monoclonal antibody,"...
The United States government signed an agreement on Friday with Sanofi S.A. and GlaxoSmithKline plc to provide up to $2.1 billion for COVID-19 vaccine testing and manufacturing.
More than half of the funds will be used to support further development of the vaccine, while the remainder will...
GlaxoSmithKline plc (GSK) and biotechnology company Medicago Inc. revealed on Tuesday a plan to jointly "develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system."
According to the...
GlaxoSmithKline plc (GSK) announced on Thursday that it will produce "one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates."
An adjuvant is a substance that boosts the immune response of a vaccine by...
British pharmaceutical company GlaxoSmithKline PLC (GSK) stated on Wednesday its revenue annually rose 19% to reach £9.09 billion in the first quarter of 2020. Furthermore, GSK's total earnings per share concurrently surged 87% to land at £0.32, with both the company's revenue and the...
GlaxoSmithKline plc (GSK) said on Monday it signed a partnership agreement with Vir Biotechnology, Inc. to work together on finding a treatment for the coronavirus.
"The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new...
British pharmaceutical company GlaxoSmithKline reported on Wednesday its earnings in the fourth quarter of fiscal 2019, with revenue standing at £8.90 billion, missing projections by around £100 million but rising 8.5% year-over-year.
However, the company surprised on the rest of the metrics,...
Pharmaceutical giant GlaxoSmithKline PLC announced on Monday that it will sell two of its travel vaccines to Bavarian Nordic for an upfront payment of €301 million.
The company noted the anti-rabies vaccines Rabipur and Encepur for the prevention of tick-borne encephalitis will continue to be...
HIV therapy company ViiV Healthcare, majority-owned by GlaxoSmithKline, announced on Thursday that its two-drug injectable HIV treatment has successfully completed its phase 3 testing.
The goal of the study was to prove whether the long-acting regimen of cabotegravir and rilpivirine,...
This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.
